Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 184 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup, 2013, Candida and Candidaemia: Susceptibility and Epidemiology, Dan. Med. J.
- Disputedcites [43] Hii, 2015, Changing epidemiology of candidemia in a medical center in middle Taiwan, J. Microbiol. Immunol. Infect. sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Farahat, 2014, Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia, Int. J. Infect. Dis. source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao, 2014, Prevalence of infectious keratitis in Central China, BMC Ophthalmol. source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning, 2017, Calling upon all public health mycologists, Eur. J. Clin. Microbiol. Infect. Dis. sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown, 2012, Hidden Killers: Human Fungal Infections, Sci. Transl. Med. source
- Partly supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Meintjes, 2014, A neglected epidemic: Fungal infections in HIV/AIDS, Trends Microbiol. source
- Not checked — no full text of the sourcecites [4] Guinea, 2010, Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome, Clin. Microbiol. Infect. source
- Not checked — no full text of the sourcecites [5] Marr, 2002, Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors, Blood source
- Not checked — no full text of the sourcecites [6] Limper, A.H., Adenis, A., Le, T., and Harrison, T.S. (2017). Fungal infections in HIV/AIDS. Lancet Infect. Dis. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning, 2013, Global fungal Burden, Mycoses, 56, 13
- The Fungal Infection Trust (2011, January 18). How common are fungal diseases?. Proceedings of the Fungal Research Trust 20th Anniversary Meeting, London, UK. Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf.
- Jayasekera, 2013, The burden of serious fungal infections in Sri Lanka, Mycoses, 56, 103
- Gugnani, 2017, Burden of serious fungal infections in Bangladesh, Eur. J. Clin. Microbiol. Infect. Dis., 36, 965, 10.1007/s10096-017-2921-z · DOI · Paper page
- Samayoa, B., Isern, V., Serra, L., Rivera, B.E., Nikiforov, M., Arathoon, E., Samayoa, C., Vallès, X., Prieto, L., and Álvarez, C. (2010, January 18–23). Preliminary results of a prospective cohort of HIV+ patients in Guatemala. Proceedings of the XVIII International AIDS Conference, Vienna, Austria.
- Gopinathan, 2002, The Epidemiological Features and Laboratory Results of Fungal Keratitis, Eye, 21, 555
Cited by
Items 901–1,000 of 2,932
Choi, M. H., Kim, D., Park, Y., & Jeong, S. H. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.08.039 · Cited by 17
Bhakt, P., Raney, M., & Kaur, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102485 · Cited by 17
Akwongo, B., Katuura, E., Nsubuga, A. M., Tugume, P., Andama, M., Anywar, G., Namaganda, M., Asiimwe, S., & Kakudidi, E. K. (2022) · Tropical Medicine and Health · doi:10.1186/s41182-022-00471-y · Cited by 17
“6 million deaths associated with overall fungal infections [1].”
BackgroundNeglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity
Li, S., Yang, X., Moog, C., Wu, H., Su, B., & Zhang, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1015775 · Cited by 17
“It is speculated that there are more than 400,000 cases of PCP worldwide each year (82, 83).”
BackgroundSastré-Velásquez, L. E., Dallemulle, A., Kühbacher, A., Baldin, C., Alcázar‐Fuoli, L., Niedrig, A., Müller, C., & Gsaller, F. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1011066 · Cited by 15
“Although several fungal species are able to cause life-threatening disease types, the highest death tolls are linked to infections by members of the genera Aspergillus, Cryptococcus, Candida and Pneumocystis [1, 2].”
BackgroundXie, F., Hao, Y., Li, L., Wang, R., Bao, J., Chi, X., Monk, B. C., Wang, T., Yu, S., Jin, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115506 · Cited by 17
The potential for rapid antigen testing for mucormycosis in the context of COVID-19
Thornton, C. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2233906 · Cited by 18
“Despite their major impact on human health, causing over 13 million infections and more than 1.5 million deaths world-wide each year [25,78], the lack of recognition of fungi as agents of lethal diseases continues.”
BackgroundInfluentialAntifungal Use and Resistance in a Lower–Middle-Income Country: The Case of Lebanon
Hassoun, N., Kassem, I. I., Hamzé, M., Tom, J. E., Papon, N., & Osman, M. (2023) · Antibiotics · doi:10.3390/antibiotics12091413 · Cited by 18
Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host–Fungal Interactions
Fusco‐Almeida, A. M., Silva, S. D. M., dos Santos, K. S., Gualque, M. W. D. L., Vaso, C. O., Carvalho, A. R., Medina‐Alarcón, K. P., Pires, A. C. M. D. S., Belizário, J. A., Fernandes, L. D. S., et al. (2023) · Journal of Fungi · doi:10.3390/jof9090943 · Cited by 17
“…the publication of T. molitor ’s transcriptome has opened doors for molecular biology studies [206]. fi cance for the insect’s survival during C. albicans infection, emphasizing its in the T. molitor ’s innate immune response is composed of both cellular and humoral components. immune system [216].”
BackgroundInfluentialChen, Y., Jiang, Q., Qing, F., Xue, J., Xiao, Q., He, W., Sui, L., & Liu, Z. (2023) · Inflammation · doi:10.1007/s10753-023-01903-5 · Cited by 16
“Approximately 7 million people worldwide are infected with C. albicans annually, which is the fourth most common pathogen in fungus blood infection [3].”
Stoia, D., Sio, L. D., Petronella, F., & Focşan, M. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116243 · Cited by 17
“Despite emerging as a global health problem and threatening the health of millions of people, fungi infections receive minimal attention compared to other pathogens (Bongomin et al., 2017).”
InfluentialUniversal digital high-resolution melting for the detection of pulmonary mold infections
Goshia, T., Aralar, A., Wiederhold, N. P., Jenks, J. D., Mehta, S. R., Karmakar, A., Monish, E. S., Sharma, A., Sun, H., Kebadireng, R., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01476-23 · Cited by 23
Achilonu, C. C., Kumar, P., Swart, H. C., et al. (2024) · BioNanoScience · doi:10.1007/s12668-024-01406-z · Cited by 15
“These outcomes are to be expected given that these microbes are ubiquitous in nature and are predominant in the environment [41, 42].”
Kamel, T., & Boulain, T. (2024) · Annals of Intensive Care · doi:10.1186/s13613-024-01309-y · Cited by 21
“While PCP is still considered a rare disease based on the European definition of fewer than five cases per 10,000 inhabitants annually, its annual number of cases worldwide could approach 500,000 cases [15].”
BackgroundOrtíz, B., Varela, D., Fontecha, G. A., Torres, K., Cornely, O. A., & Salmanton‐García, J. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae578 · Cited by 16
Babady, N. E., Chiu, C. Y., Craney, A. R., Gaston, D. C., Hicklen, R., Hogan, C. A., John, T. M., & Stewart, A. G. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2436396 · Cited by 21
“IFDs account for 13 million infections and 1.5 million deaths each year [10].”
InfluentialEstimated burden of fungal infections in Sweden
Özenci, V., Klingspor, L., Ullberg, M., Chryssanthou, E., Denning, D. W., & Kondori, N. (2019) · Mycoses · doi:10.1111/myc.12981 · Cited by 14
Self-citationPfavayi, L. T., Sibanda, E., & Mutapi, F. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000506009 · Cited by 18
Innovative therapies for invasive fungal infections in preclinical and clinical development
Yu, Y., Albrecht, K., Gröll, J., & Beilhack, A. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791819 · Cited by 19
Stevanović, N. L., Glišić, B. Đ., Vojnović, S., Wadepohl, H., Andrejević, T. P., Đurić, S., Savić, N. D., Nikodinović‐Runić, J., Djuran, M. I., & Pavić, A. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130006 · Cited by 18
Design, Synthesis and Anticandidal Evaluation of Indazole and Pyrazole Derivatives
Rodríguez‐Villar, K., Hernández‐Campos, A., Yépez‐Mulia, L., Sáinz‐Espuñes, T., Soria‐Arteche, O., Palacios‐Espinosa, J. F., Cortés‐Benítez, F., Leyte‐Lugo, M., Varela-Petrissans, B., Quintana-Salazar, E. A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14030176 · Cited by 15
“Candida albicans is the main etiologic species associated with VVC and invasive candidiasis globally [2,4,5].”
BackgroundInfluentialNanogels as Antifungal‐Drug Delivery System Against Aspergillus Fumigatus
Horvat, S., Yu, Y., Manz, H., Keller, T., Beilhack, A., Gröll, J., & Albrecht, K. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000060 · Cited by 15
Serious fungal diseases in Democratic Republic of Congo – Incidence and prevalence estimates
Kamwiziku, G. K., Makangara-Cigolo, J.-C., Orefuwa, E., & Denning, D. W. (2021) · Mycoses · doi:10.1111/myc.13339 · Cited by 16
Self-citationKakar, A., Holzknecht, J., Dubrac, S., Gelmi, M. L., Romanelli, A., & Marx, F. (2021) · Journal of Fungi · doi:10.3390/jof7060457 · Cited by 15
“5 million deaths are caused by fungal diseases annually [12,13].”
BackgroundAlaalm, L., Crunden, J. L., Butcher, M. C., Obst, U., Whealy, R. N., Williamson, C. E., O’Brien, H., Schaffitzel, C., Ramage, G., SPENCER, J. M., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.637836 · Cited by 18
Osaigbovo, I. I., & Bongomin, F. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211034266 · Cited by 17
Self-citationSeyedjavadi, S. S., Khani, S., Goudarzi, M., Zare‐Zardini, H., Shams‐Ghahfarokhi, M., Jamzivar, F., & Razzaghi‐Abyaneh, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.743346 · Cited by 15
“Over two million people are affected annually by invasive fungal diseases all over the world while fungal diseases cause more deaths every year compared with either tuberculosis or malaria (Bongomin et al., 2017).”
BackgroundDevelopment of a Multiplex PCR Short Tandem Repeat Typing Scheme for Candida krusei
van Haren, M. H. I., de Groot, T., Spruijtenburg, B., Jain, K., Chowdhary, A., & Meis, J. F. G. M. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02032-21 · Cited by 16
Dong, N., Jordan, A. E., Shen, X., Wu, X. G., Guo, X., Zhao, H., Wang, Y., Wang, D., & Fang, Q. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.815902 · Cited by 19
Azeem, H. A.-E., Osman, G. Y., El-Seedi, H. R., Fallatah, A. M., Khalifa, S. A. M., & Gharib, M. M. (2022) · Molecules · doi:10.3390/molecules27103170 · Cited by 17
“The modern global estimates have found ~700,000 cases of invasive candidiasis and 3,000,000 cases of chronic pulmonary aspergillosis [14].”
BackgroundHow Has the Aspergillosis Case Fatality Rate Changed over the Last Two Decades in Spain?
González-García, P., Alonso‐Sardón, M., Rodríguez-Alonso, B., Almeida, H., Romero‐Alegría, Á., Vega-Rodríguez, V.-J., López‐Bernús, A., Bellido, J. L. M., Muro, A., Pardo‐Lledías, J., et al. (2022) · Journal of Fungi · doi:10.3390/jof8060576 · Cited by 14
“Epidemiological studies in the mid-2000s reported a decrease in the incidence and mortality rates of IA in allogeneic HSCT and in SOT recipients.”
BackgroundInfluentialTaveira, G. B., Mello, É. D. O., Simão, T. L. B. V., Cherene, M. B., Carvalho, A. D. O., Muzitano, M. F., Lassounskaia, E., Pireda, S. F., Miguel, E. D. C., Basso, L. G. M., et al. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130218 · Cited by 17
Alves-Silva, J. M., Gonçalves, M. J., da Silva, A. B. G., Cavaleiro, C., Cruz, M. T., & Salgueiro, L. (2023) · Antibiotics · doi:10.3390/antibiotics12010179 · Cited by 17
Current Challenges and Updates on the Therapy of Fungal Infections
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/156802661907190531093808 · Cited by 18
SUMOylation in Human Pathogenic Fungi: Role in Physiology and Virulence
Sahu, M. S., Patra, S., Kumar, K., & Kaur, R. (2020) · Journal of Fungi · doi:10.3390/jof6010032 · Cited by 17
“Cryptococcal meningitis, caused predominantly by Cryptococcus neoformans, and respiratory infections including pneumonia, due to Pneumocystis jirovecii, are prevalent in Human Immunodeficiency Virus (HIV)-infected patients [47,59,60].”
BackgroundInfluentialShin, J. H., Kim, S. H., Lee, D., Lee, S. Y., Chun, S., Lee, J. H., Won, E. J., Choi, H., Choi, H.-W., Kee, S. J., et al. (2020) · Annals of Laboratory Medicine · doi:10.3343/alm.2021.41.2.214 · Cited by 14
Choopara, I., Teethaisong, Y., Arunrut, N., Thunyaharn, S., Kiatpathomchai, W., & Somboonna, N. (2021) · PeerJ · doi:10.7717/peerj.11082 · Cited by 16
Fungal cell death: The beginning of the end
Rico-Ramírez, A. M., Gonçalves, A. P., & Glass, N. L. (2022) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2022.103671 · Cited by 19
Organoselenium compounds as an enriched source for the discovery of new antimicrobial agents
Friberg, L. I. M., Kavanagh, A. M., Amado, M., Lowe, G. J., Zuegg, J., de Paula, M. N., Onawole, A. T., Floyd, H. E. E., Кравченко, А. Н., Guan, D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00677a · Cited by 14
Nemr, A. A., Farag, M. M., Hegazy, D., Attia, H., & Abdelhakeem, E. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107477 · Cited by 17
Wensing, L., & Shapiro, R. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1720-5_4 · Cited by 10
Candida meningitis/ventriculitis over a decade. Increased morbidity and length of stay a concern
Kelly, L., Walsh, J., Skally, M., Dinesh, B., Burns, K., O’Connell, K., MacNally, S. P., Humphreys, H., & Fitzpatrick, F. (2022) · British Journal of Neurosurgery · doi:10.1080/02688697.2022.2054947 · Cited by 16
D’Auria, F. D., Casciaro, B., Angelis, M. D., Marcocci, M. E., Palamara, A. T., Nencioni, L., & Mangoni, M. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116345 · Cited by 21
“The past two decades have seen a dramatic increase in fungal infections, causing an emergency, particularly in hospitalized patients and immunocompromised individuals [1,2].”
BackgroundShaw, K. J. (2022) · Journal of Fungi · doi:10.3390/jof8090909 · Cited by 20
“Global estimates of life-threatening invasive fungal infections exceed 3 million infections per year and include 3 million cases of chronic pulmonary aspergillosis and >300,000 cases of serious and life-threatening invasive aspergillosis (IA) infections [1].”
BackgroundStrategies to improve the diagnosis and clinical treatment of dermatophyte infections
Durdu, M., & İlkit, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2144232 · Cited by 17
“5 million people worldwide every year [21].”
Sen, P., Gupta, L., Vijay, M., Sarin, M. V., Shankar, J., Hameed, S., & Vijayaraghavan, P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1103957 · Cited by 14
Aneuploidy Is Associated with Azole Resistance in Aspergillus fumigatus
Khateb, A., Gago, S., Bromley, M., Richardson, M., & Bowyer, P. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01253-22 · Cited by 14
“Estimated mortality for chronic disease is about 400,000 per year (2).”
BackgroundSelf-citationModern Technologies in Diagnosis of Fungal Keratitis (Review)
Sitnova, A. V., & Svetozarskiy, S. N. (2023) · Современные технологии в медицине · doi:10.17691/stm2023.15.2.07 · Cited by 19
“Thus, in 2017–2019, the corneal mycosis morbidity did not fall below 1 million cases per year [7, 8].”
BackgroundBidaud, A.-L., Sabater, A. M., Normand, A., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01716-22 · Cited by 14
Characterization of Lung Inflammatory Response to Aspergillus fumigatus Spores
Bouyssi, A., Déméautis, T., Trécourt, A., Delles, M., Agostini, F., Monneret, G., Gléhen, O., Wallon, M., Persat, F., Devouassoux, G., et al. (2023) · Journal of Fungi · doi:10.3390/jof9060682 · Cited by 16
“Furthermore, the increased use of immunosuppressants such as corticosteroids, anticancer chemotherapies and biotherapies in recent decades resulted in a higher worldwide incidence of aspergillosis [11,12].”
BackgroundQiao, Y., Tao, Z., Hao, F., Huang, Y., Sun, H. L., & Guo, P. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s411283 · Cited by 16
Usach, I., Martínez-Álvarez, P., & Peris, J. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123287 · Cited by 14
Tufa, T. B., Bongomin, F., Fathallah, A., Cândido, A. L. S. M., Hashad, R., Abdallaoui, M. S., Nail, A. M. A., Fayemiwo, S. A., Penney, R. O. S., Orefuwa, E., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.08.015 · Cited by 14
“5 million annual cases of invasive fungal infections (IFIs) due to opportunistic fungal pathogens such Aspergillus species, Candida species, Cryptococcus species, and Pneumocystis species are estimated to occur particularly in immunocompromised patients [1].”
BackgroundSelf-citationMudenda, S., Matafwali, S. K., Mukosha, M., Daka, V., Chabalenge, B., Chizimu, J. Y., Yamba, K., Mufwambi, W., Banda, P., Chisha, P., et al. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlad141 · Cited by 21
Multifunctional Gold Nanozyme‐Engineered Amphotericin B for Enhanced Antifungal Infection Therapy
Jiang, C., Li, F., Pei, S., Wen, M., Yang, S., Geng, T., Shao, D., Shi, J., & Shang, L. (2024) · Small · doi:10.1002/smll.202312253 · Cited by 15
Liu, A., Xiong, L., Wang, L., Han, Z., Gan, X., Zou, M., & Wang, X. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09477-9 · Cited by 15
Potential antifungal applications of heterometallic silica nanohybrids: A synergistic activity
Yapa, P. N., Munaweera, I., Weerasekera, M. M., Weerasinghe, L., & Sandaruwan, C. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213930 · Cited by 14
Nayak, A., Khedri, A., Chavarria, A., Sanders, K. N., Ghalei, H., & Khoshnevis, S. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00040-9 · Cited by 18
Srisurapanont, K., Lerttiendamrong, B., Meejun, T., Thanakitcharu, J., Manothummetha, K., Thongkam, A., Chuleerarux, N., Sanguankeo, A., Li, L. X., Leksuwankun, S., et al. (2024) · Mycoses · doi:10.1111/myc.13798 · Cited by 17
“Firstly, the prevalence of candidemia could be underestimated in low-and middle-income countries due to diagnostic limitations in Candida spp. detection [112, 113].”
Mehandi, R., Twala, C., Ahmedi, S., Fatima, A., Islam, K. U., Rana, M., Sultana, R., Manzoor, N., Javed, S., Haque, M. M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2292796 · Cited by 15
“More than 75,000 hospital admissions and over 9 million outpatient visits for fungi-related illnesses occur each year, with Candida being the primary cause, especially among patients in the intensive care unit (Bongomin et al., 2017).”
Shah, M., Zia, M., Ahmad, I., Khan, M. U., Ejaz, H., Alam, M., Aziz, S., Nishan, U., Dib, H., Ullah, R., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1537872 · Cited by 25
“…asthma, chronic pulmonary aspergillosis, fungal keratitis, invasive candidiasis, fungal pneumonia, invasive aspergillosis, cryptococcal meningitis in HIV/AIDS patients, and disseminated histoplasmosis, are linked with fungal diseases (Denning, 2015; Bongomin et al., 2017; Rajasingham et al., 2017).”
In vitro interaction of Candida tropicalis biofilm formed on catheter with human cells
Bonato, F. G. C., Sakita, K. M., de Oliveira, A. G., Mendonca, P., Crivellenti, L. Z., Negri, M., & Svidzinski, T. I. E. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.09.029 · Cited by 17
Molecular simulations of fluconazole-mediated inhibition of sterol biosynthesis
Siqueira, T. H., & Martínez, L. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1614998 · Cited by 19
“This is a major problem as fluconazole is the most commonly used antifungal agent for prophylaxis and treatment of Candida infections in many parts of the world (Bongomin et al., 2017; Castanheira, Messer, Jones, Farrell, & Pfaller, 2014; Pfaller et al., 2014).”
BackgroundInfluentialUsing Artificial Intelligence in Fungal Lung Disease: CPA CT Imaging as an Example
Angelini, E. D., & Shah, A. (2021) · Mycopathologia · doi:10.1007/s11046-021-00546-0 · Cited by 16
“Global estimates of CPA are ~ 3 million cases; however, again there is little national prevalence data to be precise [5].”
BackgroundPolyacetylene Glycosides: Isolation, Biological Activities and Synthesis
Santos, J. A. M., Santos, C. L. A. A., Filho, J. R. D. F., Menezes, P. H., & Freitas, J. C. R. (2021) · The Chemical Record · doi:10.1002/tcr.202100176 · Cited by 16
Targeting immunometabolism in host-directed therapies to fungal disease
Gonçalves, S. M., Ferreira, A. V., Cunha, C., & Carvalho, A. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab014 · Cited by 16
Ceballos-Garzón, A., Román, E., Plá, J., Pagniez, F., Amado, D., Alméciga-Díaz, C. J., Pape, P. L., & Parra‐Giraldo, C. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265777 · Cited by 14
“6 million deaths (similar to tuberculosis and 3-fold higher than malaria infections) have become a public health problem [1, 2].”
BackgroundPalliyil, S., Mawer, M., Alawfi, S. A., Fogg, L. G., Tan, T. H., Cesare, G. B. D., Walker, L. A., MacCallum, D. M., Porter, A. J., & Munro, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01957-21 · Cited by 20
Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease
Nwankwo, L., Gilmartin, D., Matharu, S. S., Nuh, A., Donovan, J., Armstrong-James, D. P. H., & Shah, A. (2022) · Journal of Fungi · doi:10.3390/jof8040362 · Cited by 13
“The global estimate of patients living with chronic pulmonary fungal disease is substantial, with ~5 million individuals with ABPA and ~3 million individuals with CPA, respectively [4,5].”
BackgroundSchleusener, J., Lohan, S. B., Busch, L., Ghoreschi, K., Ploch, N. L., May, S., Vogel, S., Eberle, J., & Meinke, M. C. (2022) · Mycoses · doi:10.1111/myc.13521 · Cited by 14
Wang, X., Liu, P., Jiang, Y., Han, B., & Yan, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.992275 · Cited by 16
“Approximately 1.7 million annual lethality is attributed to lethal invasive fungal infections, which is comparable to those due to tuberculosis or AIDS, and more than those owing to malaria, breast tumor, or prostate cancer (Brown et al., 2012; Kainz et al., 2020).”
BackgroundInfluentialCharacteristics of the Skin Microbiome in Selected Dermatological Conditions: A Narrative Review
Olunoiki, E., Rehner, J., Bischoff, M., Koshel, E. I., VOGT, T. M., Reichrath, J., & Becker, S. L. (2022) · Life · doi:10.3390/life12091420 · Cited by 16
Microfluidics combined with fluorescence in situ hybridization (FISH) for Candida spp. detection
Barbosa, V. B., Rodrigues, C. F., Cerqueira, L., Miranda, J. M., & Azevedo, N. F. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.987669 · Cited by 14
“Candiduria denotes a diagnostic and therapeutic challenge for physicians from primary care or infectious diseases, intensive medicine and surgery (Bongomin et al., 2017), because it may be linked to numerous conditions that require careful interpretation, from sample contamination to UTI or even disseminated candidias…”
BackgroundAntibodies to Combat Fungal Infections: Development Strategies and Progress
Rabaan, A. A., Alfaraj, A. H., Alshengeti, A., Alawfi, A., Alwarthan, S. M., Alhajri, M. M., Al-Najjar, A. H., Fares, M. A. A., Najim, M. A., Almuthree, S. A., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11030671 · Cited by 18
“9 million people are affected by invasive or persistent fungal diseases [11].”
BackgroundOladele, R. O., Osaigbovo, I. I., Ayanlowo, O. O., Otu, A. A., Hoenigl, M., Cornely, O. A., Chakrabarti, A., & Denning, D. W. (2018) · Mycoses · doi:10.1111/myc.12845 · Cited by 15
Self-citationSynergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms
Tu, B., Yin, G., & Li, H. (2020) · BMC Microbiology · doi:10.1186/s12866-020-1718-x · Cited by 17
Xu, Y., Chen, M., Zhu, J., van den Ende, B. G., Chen, A. J., Al‐Hatmi, A. M. S., Li, L., Zhang, Q., Xu, J., Liao, W., et al. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s281288 · Cited by 14
“cause a wide spectrum of human diseases and affect more than 14 million people worldwide.(7,41) Diverse Aspergillus spp.”
BackgroundMolecular Epidemiology of Aspergillus fumigatus in Chronic Pulmonary Aspergillosis Patients
van der Torre, M. H., Shen, H., Rautemaa‐Richardson, R., Richardson, M. D., & Frazer, L. N. (2021) · Journal of Fungi · doi:10.3390/jof7020152 · Cited by 17
“Approximately three million people worldwide suffer from CPA and the global burden is thought to be significantly higher in Asia compared to other continents [19].”
BackgroundNjovu, I. K., Musinguzi, B., Mwesigye, J., Kassaza, K., Turigurwa, J., Nuwagira, E., Bazira, J., Taseera, K., Mpeirwe, M., Ampaire, L., et al. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211042477 · Cited by 20
Voronin, A. P., Vasilev, N. A., Surov, A. O., Churakov, A. V., & Perlovich, G. L. (2021) · CrystEngComm · doi:10.1039/d1ce01353j · Cited by 14
Humelnicu, A.-C., Samoilă, P., Cojocaru, C., Dumitriu, R. P., Bostănaru, A.-C., Mareș, M., Harabagiu, V., & Simionescu, B. C. (2022) · Polymers · doi:10.3390/polym14040689 · Cited by 15
“More than one billion people are affected by superficial Candida infections as oral candidiasis and vaginitis (vulvovaginal candidiasis) [1,2].”
BackgroundUnraveling Caspofungin Resistance in Cryptococcus neoformans
Papon, N., & Goldman, G. H. (2021) · mBio · doi:10.1128/mbio.00156-21 · Cited by 17
“Although the epidemiology of these fungal diseases has substantially changed in the past few decades, Candida albicans and Aspergillus fumigatus but also Cryptococcus neoformans remain the prominent causative agents of the most life-threatening forms and are responsible for 1 million deaths a year worldwide (3).”
BackgroundStewart, R. M. R., Gold, J. A. W., Chiller, T. M., Sexton, D. J., & Lockhart, S. R. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2227790 · Cited by 15
A review on lactoferrin as a proton pump inhibitor
Santos-Pereira, C., Andrés, M. T., Fierro, J. F., Rodrigues, L. R., & Côrte-Real, M. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.075 · Cited by 13
Targeting biofilm formation in Candida albicans with halogenated pyrrolopyrimidine derivatives
Kim, Y., Jeon, H., Boya, B. R., Lee, J., & Lee, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117528 · Cited by 14
O’Donnell, S., Rezende, G. D., Vernadet, J., Snirc, A., & Ropars, J. (2025) · Genome Biology and Evolution · doi:10.1093/gbe/evaf125 · Cited by 20
“Aspergillus fumigatus is currently the major airborne fungal pathogen, with a relatively high incidence and mortality, comparable to Candida and Cryptococcus species (Bongomin et al. 2017; Denning 2024).”
Lopes-Bezerra, L. M., Mora-Montes, H. M., & Bonifáz, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-64113-3_10 · Cited by 26
Zajta, E., Csonka, K., Tóth, A., Tiszlavicz, L., Németh, T., Orosz, A., Novák, Á., Csikós, M., Vágvölgyi, C., Mócsai, A., et al. (2021) · mBio · doi:10.1128/mbio.01608-21 · Cited by 16
“000 (4), and they are associated with a mortality of ;30 to 75% (5, 6).”
BackgroundWall, D. A., Tarrant, S., Wang, C., Mills, K. V., & Lennon, C. W. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.752824 · Cited by 15
“These fungal species cause pulmonary infections in humans such as cryptococcosis, histoplasmosis, and aspergillosis, respectively, which pose a particular threat to immunosuppressed individuals (Bongomin et al., 2017).”
BackgroundVaso, C. O., Bila, N. M., Pandolfi, F., Vita, D. D., Bortolami, M., Bonatti, J. L. C., da Silva, R. A. M., Gonçalves, L. N. C., Tudino, V., Costi, R., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051043 · Cited by 15
Occidiofungin: Actin Binding as a Novel Mechanism of Action in an Antifungal Agent
Hansanant, N., & Smith, L. (2022) · Antibiotics · doi:10.3390/antibiotics11091143 · Cited by 14
“Fungal infections constitute a large financial and medical burden globally, with over a million deaths associated with fungal infections globally every year [1].”
BackgroundNon-Aspergillusmould lung infections
Puerta‐Alcalde, P., & García‐Vidal, C. (2022) · European Respiratory Review · doi:10.1183/16000617.0104-2022 · Cited by 14
Wang, Y., Long, W., Zhang, F., Zhang, M., Zeng, K., & Zhu, X. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02438-22 · Cited by 13
Bowring, B. G., Sethiya, P., Desmarini, D., Lev, S., Le, L. T., Bahn, Y., Lee, S., Toh‐e, A., Proschogo, N. W., Savage, T., et al. (2023) · mBio · doi:10.1128/mbio.03551-22 · Cited by 16
Discovery of a new chemical scaffold for the treatment of superbug Candida auris infections
Tu, J., Zhu, T., Wang, Q., Yang, W., Huang, Y., Xu, D., Liu, N., & Sheng, C. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2208687 · Cited by 13
“Fungal diseases caused by drug-resistant pathogens are estimated to kill nearly 2 million people and infect billions of immunocompromised populations each year, including patients undergoing cancer chemotherapy and organ transplant and infected with human immunode fi ciency virus (HIV) [3,4].”
BackgroundLakoh, S., Kamara, J. B., Orefuwa, E., Sesay, D. K. D., Jiba, D. F., Adekanmbi, O. A., Deen, G. F., Russell, J. B., Bah, A. B., Kargbo, M. J., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011284 · Cited by 15
Self-citationZhang, Y., Wang, S., Zhou, C., Zhang, Y., Pan, J., Pan, B., Wang, B., Hu, B., & Guo, W. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s417840 · Cited by 16
“The annual incidence of CPA and IA in the world is estimated to be 3 million cases and over 250,000 cases, respectively.(4) The case-fatality rate associated with aspergillosis has been reported to be 20%–72% depending on the underlying conditions of the patients.”
BackgroundEades, C. P., Bakri, A., Lau, J. C. Y., Moore, C. B., Frazer, L. N., Richardson, M. D., & Rautemaa‐Richardson, R. (2023) · Journal of Fungi · doi:10.3390/jof9080813 · Cited by 13
“It is the most common invasive fungal disease globally [1].”
BackgroundAntibiofilm Effect of Lavandula multifida Essential Oil: A New Approach for Chronic Infections
Alves-Silva, J. M., Zuzarte, M., Cavaleiro, C., & Salgueiro, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082142 · Cited by 18
“5 million annual deaths [1], with candidiasis being the most predominant type [10].”
BackgroundFruits are vehicles of drug-resistant pathogenic Candida tropicalis
Chen, Y.-Z., Tseng, K., Wang, S., Huang, C.-L., Lin, C.-C., Zhou, Z.-L., Tsai, D.-J., Lin, C.-M., Chen, Y.-L., Chen, K.-T., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01471-23 · Cited by 16
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.